ストックスクリーナーアプリを入手
27.46
5.13%
1.34
前日終値:
$26.12
開ける：
$26.21
24時間の取引高:
8.48M
Relative Volume:
0.77
時価総額：
$10.27B
収益：
$3.14B
当期純損益:
$-3.36B
株価収益率:
-3.1455
EPS:
-8.73
ネットキャッシュフロー:
$-4.03B
1週間 パフォーマンス:
+3.39%
1か月 パフォーマンス:
+12.40%
6か月 パフォーマンス:
-38.21%
1年 パフォーマンス:
-82.25%
1日の値動き範囲:
$26.12
$27.55
1週間の範囲:
$25.82
$28.57
52週間の値動き範囲:
$23.15
$153.56
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.46 | 10.27B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
DraftKings, Teladoc, Rush Street Interactive, Moderna, and Avis Budget Group Shares Are Soaring, What You Need To Know - Yahoo
Is Moderna Stock A Buy After Winning A Surprise Approval? - Investor's Business Daily
Green Alpha Advisors LLC Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s human/AI revampthe human implications and how to manage them - Diginomica
How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks? - MSN
How Is Moderna’s Stock Performance Compared To Other Biotechnology Stocks? - Barchart.com
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of “Hold” by Brokerages - Defense World
Trump administration cancels Moderna contract to fight bird flu and other viruses - news8000.com
Moderna at Jefferies Conference: Strategic Growth and Challenges - Investing.com
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
Transcript : Moderna, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 10 - marketscreener.com
Moderna’s HR-IT merger: Trend or exception to the rule? - cio.com
Fed. Circ. Upholds Moderna's IP Win Over COVID Vax - Law360
Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News
Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O
CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com
Class Action Filed Against Moderna, Inc. (MRNA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
US appeals court sides with Moderna on COVID patent claims - Reuters
Moderna Will Test New Covid Shot Against Placebo, RFK Jr. Says - MSN
Moderna (MRNA) to Conduct New Trial for Next-Gen COVID Vaccine - GuruFocus
RFK Jr. says Moderna agreed to another clinical trial to support new COVID shot - Seeking Alpha
15,000 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Alpha Wealth Funds LLC - MarketBeat
Down 80%, Should You Buy the Dip on Moderna? - AOL.com
Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says - whbl.com
Moderna will test new Covid shot against Placebo, Robert F Kennedy Jr. says - CNBC TV18
Moderna (MRNA) Will Test New Covid Shot Against Placebo, RFK Jr. Says - Bloomberg
CDC official resigns from COVID vaccine committee advisory role, sources say - marketscreener.com
FDA grants limited approval to Moderna’s new mRNA COVID vaccine By Investing.com - Investing.com Canada
Moderna's (MRNA) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike - Zacks Investment Research
Moderna (MRNA) Faces Challenges Amid Potential Regulatory Shifts | MRNA Stock News - GuruFocus
Moderna (NASDAQ:MRNA) Given Market Perform Rating at William Blair - Defense World
How Moderna Went From Pandemic Hero to Vaccine Victim - WSJ
Moderna (MRNA) Faces Challenges with mRNA Technology Focus | MRNA Stock News - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Takes $18.08 Million Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
LVW Advisors LLC Invests $298,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Lansforsakringar Fondforvaltning AB publ Invests $4.49 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
California State Teachers Retirement System Has $20.83 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
HHS cancels funding for Moderna vaccines to fight pandemic flu - WATE 6 On Your Side
What you need to know about Moderna’s new COVID vaccine, just approved by the FDA - AOL.com
Market movers: Moderna, Cleveland Cliffs, Nucor, US Gold... - Proactive financial news
FDA approves Moderna's new COVID-19 vaccine - CIDRAP
Moderna (MRNA) Faces Multiple Regulatory Challenges - Insider Monkey
Two biopharma stocks to consider outside of Moderna - Yahoo
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful (NASDAQ:MRNA) - Seeking Alpha
New Moderna COVID-19 vaccine approved by FDA for adults 65 and older - CBS News
Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More - Yahoo Finance
Moderna's COVID-19 vaccine mNEXSPIKE gains FDA approval - TechTarget
Moderna moves higher on FDA approval of new COVID-19 vaccine - Proactive financial news
Moderna's New Vaccine mNEXSPIKE Approved by FDA, Shares RiseNews and Statistics - IndexBox
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):